NVS Stock Recent News

Novartis receives third FDA approval for oral Fabhalta ® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)

NVS reports new safety and efficacy data from the phase III program for its investigational OAV101 IT gene therapy for SMA patients.

Swiss drugmaker Novartis is ending its use of diverse panels for all of its hiring in the United States, the company told Reuters on Wednesday, citing the changing legal and policy landscape surrounding diversity in the U.S.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?

Swiss pharmaceutical giant Novartis says it is watching "very carefully" how the reciprocal tariff policy proposed by the United States would unfold in early April, Chief Executive Vas Narasimhan said in Tokyo. U.S. President Donald Trump last month flagged potential import duties of about 25% on pharmaceuticals as part of measures affecting other industries, including semiconductors and automobiles, as he seeks to reshape global trade.

Dublin, March 14, 2025 (GLOBE NEWSWIRE) -- The "Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. A newly revealed comprehensive overview of the circulating DNA/RNA patent landscape discloses remarkable industry growth projections, with an expected surge from USD 5.32 billion in 2023 to USD 16.4 billion by 2032. The market is advancing at an impressive compound annual growth rate (CAGR) of 13.29%, driven by innovations in nucleic acid-based therapeutics and diagnostics. Patent Landscape Overview The report provides a thorough examination of blood-based biomarkers critical for non-invasive diagnostics in various conditions ranging from cancer to genetic disorders. The increasing number of patents in next-generation sequencing, cancer biomarkers, and therapeutic delivery systems are significantly shaping the industry landscape, propelling advancements in non-invasive diagnostics and personalised medicine. Regio

The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based firm Novartis , a league source told Reuters on Thursday.

BOSTON, March 13, 2025 (GLOBE NEWSWIRE) -- Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence initiative supporting individuals with IgA nephropathy. This ground-breaking study will leverage Folia's cutting-edge technology platform, allowing participants to track changes and quality of life impacts based on the symptoms most relevant to them- whether commonly associated with IgAN or not- alongside their individual treatment plan during an initial six-month observational period. By enabling participants to self-select and define what's most relevant to them, rather than relying solely on pre-specified patient-reported outcomes (PROs), this approach provides a comprehensive and nuanced understanding of the lived experiences of IgAN.

If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.

Basel, March 7, 2025 – Novartis shareholders today agreed to the Board of Directors' recommendations for all proposed resolutions at the company's Annual General Meeting (AGM). A total of 1,693 shareholders were present at the meeting held in Basel, representing approximately 57.42% of the issued shares of Novartis.